The promise of genomics is to understand human biology, improve health and well being and better treat disease. While the genome reflects all the DNA in our cells, much of the work to date has focused on a subset of that DNA, the exome. This is the part of the genome that represents the genes that code for the proteins, fats and carbohydrates that make up our cells, organs and body. The exome constitutes only 2% of the genome, the rest having regulatory and other roles that are very poorly, or not at all understood at this time.

There remains an enormous gap in our understanding of the cell and what happens to it that leads to disease.

Bringing diversity is a key pillar to solve this puzzle. Along with this diversity, it is equally important to get information about the population’s disease traits. That is, drug researchers require genomic data from curated disease cohorts, with deep phenotyping and the biorepository itself for further context-dependent investigations. This is what Anuva’s Genomic Bio/Data Bank delivers to them!

Curated disease cohorts + Deeply phenotyped + Diverse Asian populations + Genomic sequence data + Biorepository = Genomic Bio/Data Bank

The genome is complex: the number of possible variations is greater than the estimated number of atoms in the universe and that does not even take account of the multiplicity of environmental, epigenetic, and other factors that impact the function of genes and other genetic elements within the genome. Yet, the problem is surmountable.

The Genomic Bio/Data Bank paradigm enables researchers to identify differences in disease susceptibility as well as the consequences of treatments between different peoples and populations, allowing a shortcut past the Gordian complexity of permutations.

Furthermore, as we tease out the pathways highlighted by this diversity, the biological threads that lead away from health towards disease will be laid bare. This will open up a myriad of treatment opportunities.

Thus, Anuva’s Bio/Data Bank paradigm creates new knowledge that helps drug researchers uncover root causes of diseases, find treatment targets and also their effect on individuals.

Dr. Jonathan Picker Chief Executive Office

Dr. Jonathan Picker is an affiliate faculty member and clinical geneticist at Boston's Children's Hospital, Harvard Medical School.

With 25 years of experience in Pediatrics and Genetics, Dr. Picker specializes in the interface of clinical care and applied genetic and genomic research. Dr. Picker's research spans diagnostic tools in genetics to descriptive analysis of rare disorders to molecular neuroscience. He was the co-founder and Director of the first Pediatric Pharmacogenomic clinic in the USA; as well as Director of the Harvard Medical School Advanced Human Genetics Training Program Course.

Dr. Picker is the recipient of various prestigious awards, including the first Sidney R. Baer Jr. Prize for Mental health Research. He has authored numerous research papers involving informative cases, molecular biology, behavioral neuroscience, applied clinical genetic guidelines as well as invited reviews and chapters.

Dr. Picker holds a bachelor's degree of Medical Biology in Genetics, and an MBChB in Medicine from Aberdeen University, UK. He also holds an MS in Genetics and Biochemistry and a PhD in Molecular Biology from Newcastle University, UK.

Kushagra SharmaPresident & Board Member

Kushagra Sharma is a seasoned business leader with a career spanning entrepreneurship as well as general management, Kushagra has deep expertise in developing and executing business plans in start-ups as well as large corporations. He is responsible for the revenue growth of the business, strategic planning, and partnerships at Anuva.

Before joining Anuva, he was responsible for the strategy and project execution in launching 4G digital services for Reliance Jio in India. Kushagra has previously served in leadership roles in companies like British Telecom, MTS Sistema Shyam, Grail Research and Evalueserve.

He holds a bachelor's degree from Indian Institute of Technology, Delhi and an MBA from INSEAD, Fontainebleau.

Dr. Asmi ShahVice President of Data and Technology

Dr. Asmi Shah brings in her data science expertise in dealing with big data, managing and standardizing multidisciplinary large scale biological datasets in the field of drug discovery through genomics and phenomics. She is responsible for the research and development of end to end software products and workflows.

Before joining Anuva, she contributed to the research of drug discovery done with the use of high content/throughput screening on various zebrafish assays at University of Heidelberg in Germany and at Harvard Medical School, USA. She has also taken up various technical roles in product management and software R&D with different corporate industries such as Intel, Rambus and Inform Technologies in the USA and with data analytics startups in India.

Dr. Shah holds a bachelor’s degree from Saurashtra University, India, an MS from San Jose State University, USA and has pursued her PhD from University of Heidelberg, Germany under a Marie Curie fellowship.

Abhishek Kumar Chairman & Executive Director

Abhishek Kumar brings in extensive experience of acquiring, merging, carving out and repositioning companies globally. He founded Joulon - a KKR company, and has led large scale distributed businesses globally.

He holds a bachelor’s degree from Indian Institute of Technology, Kanpur and an MBA from Harvard Business School.